Physician profile
Sameen Bozai
NPI 1508519240
$6,641.85
in general payments reported to CMS, 2019-2025
27 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.38 · 2023: $4,253 · 2024: $1,314 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,481 · Travel and Lodging: $1,081 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,481.25 |
| Travel and Lodging | $1,081.38 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,505.50 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $1,585.27 | 2022-2024 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $523.17 | 2023-2025 | Caplyta |
| Alkermes, INC. | $463.55 | 2023-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $365.18 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $191.49 | 2023-2024 | Ingrezza |
| Lilly USA, LLC | $106.24 | 2022-2025 | Amyvid, Kisunla |
| Astrazeneca Pharmaceuticals LP | $102.91 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Lundbeck LLC | $102.52 | 2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $96.54 | 2023-2024 | Austedo, Austedo Xr, Uzedy |
| Novo Nordisk INC | $80.51 | 2024-2025 | Wegovy |
| Idorsia Pharmaceuticals US INC | $70.36 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $70.13 | 2023-2024 | Fanapt, Hetlioz |
| Daiichi Sankyo INC. | $58.98 | 2024-2025 | Injectafer |
| Corium, LLC | $52.63 | 2023-2024 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $33.01 | 2023 | Methylphenidate Hydrochloride |
| Phathom Pharmaceuticals, INC. | $29.41 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.00 | 2025 | Jardiance |
| Astellas Pharma US INC | $24.50 | 2024 | Veozah |
| Almatica Pharma LLC | $24.22 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $23.94 | 2023 | Trintellix |
| Optinose US, INC. | $21.78 | 2025 | |
| Noven Therapeutics, LLC | $19.93 | 2024 | Xelstrym |
| Exact Sciences Corporation | $18.50 | 2025 | The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $18.34 | 2024 | Auvelity |
| Neos Therapeutics, LP | $17.45 | 2024 | Adzenys Xr-Odt |
| Brainsway USA INC | $10.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameen Bozai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.